Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Metastatic Solid Tumors 2Melanoma 2Solid Tumors 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoplasms 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Breakthrough Pain 1Biliary Tract Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Infusions, Intravenous × Clear all
NCT01023958 2017-11-22

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Boehringer Ingelheim

Phase 2 Completed
50 enrolled 29 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡